Guardant Health Expands Shield MCD Test to Asia via Manulife Partnership
Event summary
- Guardant Health launched its Shield™ multi-cancer detection (MCD) test in multiple Asian markets, partnering with Manulife to offer the test to eligible customers in Hong Kong, Singapore, and the Philippines starting April 2026.
- The Shield MCD test is a methylation-based blood test designed to detect 10 common cancer types in individuals aged 45 or older.
- Manulife, a major insurer in Asia, will integrate the Shield MCD test into its health offerings, marking the first such collaboration with a major insurer in the region.
- The Shield MCD test has received Breakthrough Device Designation from the U.S. FDA based on its performance in predicting cancer presence and tissue of origin.
The big picture
Guardant Health's expansion into Asia with the Shield MCD test underscores the growing demand for early cancer detection solutions in regions with high cancer mortality rates. The partnership with Manulife, a major insurer, highlights the strategic importance of integrating innovative health technologies into existing insurance frameworks to improve health outcomes. This move positions Guardant Health to capitalize on the increasing focus on preventive healthcare in Asia.
What we're watching
- Market Adoption
- How quickly the Shield MCD test will be adopted by other insurers and healthcare providers in Asia, given its first-of-its-kind partnership with Manulife.
- Regulatory Approval
- Whether the Shield MCD test will receive similar regulatory endorsements in Asia as it has in the U.S., which could accelerate its market penetration.
- Competitive Dynamics
- The pace at which competitors will introduce similar multi-cancer detection technologies, potentially impacting Guardant Health's market share.
Related topics